Greg Glenn

Dr. Greg Glenn serves as President of Research and Development at Novavax and is responsible for leading Novavax’ recombinant nanoparticle RSV F vaccine program. Greg joined Novavax following the acquisition of the publicly-traded biotechnology company IOMAI by Intercell. As a founder of IOMAI, Greg conducted pioneering work in vaccine antigen delivery via skin patch technology and succeeded in bringing several products from early concept into late-stage clinical development, evaluated in 35 clinical trials. Greg has published over 70 primary research and review articles, holds multiple U.S., European, and other international patents and is a recognized innovator and leader in the field of vaccine delivery, discovery and translation to development. He trained in pediatrics at Madigan Army Medical Center, was board certified in Pediatrics, and completed a Medical Research Fellowship at the Walter Reed Army Institute of Research in Washington, D.C., where he worked in translational vaccine research from 1992 until 2000. 

Greg earned his B.A. degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine.  He and his wife are members of Fourth Presbyterian Church in Bethesda, MD.